Charles River Launches nAAVigation Vector Platform

Charles River Laboratories International, Inc. has launched its nAAVigation Vector Platform (nAAVigation), a platform which streamlines the pathway to GMP Adeno-Associated Virus (AAV) vector manufacturing without the need for significant process development. According to the company, the nAAVigation platform has the capability to reduce a program’s timeline to GMP for viral vector gene therapy developers by 55 percent, translating to fewer than eight months compared to traditional manufacturing workflows.
 
Charles River’s nAAVigation approach is based on a high-productivity HEK293 suspension cell line, which is amenable to clients’ scale-up and serotype needs. nAAVigation uses an optimized single-use upstream approach coupled with robust downstream purification processes, enabling client AAV programs to scale up to 500L in suspension. The nAAVigation platform is designed to accelerate time to clinic by leveraging established development processes, on-hand materials, templated documents, and 100 percent qualified, in-house analytics.